Patients with plaque psoriasis and comorbid psoriatic arthritis who started risankizumab (Skyrizi) were less likely to stop or switch therapy over 37 months than those who started other biologics. The findings come from the final results of the VALUE study, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada.¹
The difference was largest compared with tumor necrosis factor inhibitors (TNFi), while differences compared with interleukin (IL)-17 inhibitors weren’t statistically significant.¹ The results build on an interim analysis presented at the 2025 Fall Clinical meeting, which showed higher drug survival with risankizumab at 25 months in the same population.²
About one-third of patients with psoriasis develop psoriatic arthritis, and this combination requires durable therapy to control both skin and joint disease over time.¹ Drug survival, or how long those being treated stay on a given biologic, is known to be a real-world marker of long-term treatment success.
How Was the VALUE Study Designed?
VALUE (NCT03982394) is a multicountry, prospective, observational study. It enrolled adults with moderate to severe psoriasis prescribed either risankizumab, an IL-23 p19 inhibitor, or another biologic according to local labeling, in a 2:1 ratio.¹ This post hoc analysis focused on 462 patients with psoriatic arthritis diagnosed by a rheumatologist.
To balance baseline characteristics, investigators used 1:1 propensity score matching, with exact matching on prior biologic use, which produced 121 patients per group.¹ The groups were comparable at baseline:
- Mean age: 51.0 years with risankizumab and 50.4 years with other biologics
- Mean Psoriasis Area and Severity Index score: 14.0 and 14.1
- Mean affected body surface area: 21.7% and 20.2%
- Biologic-naive: 56.2% in each group¹
Investigators defined drug survival as continued use of the biologic received at enrollment. A drug change meant stopping the biologic or switching to another.¹ The reported P values are nominal.
How Did Risankizumab Drug Survival Compare With Other Biologics?
By month 37, 18.2% (22/121) of risankizumab recipients had a drug change, compared with 33.1% (40/121) of patients receiving other biologics (P < .01).¹ Kaplan-Meier estimates of the probability of a drug change were shown to be 0.20 (95% CI, 0.14-0.30) with those in the risankizumab arm and 0.35 (95% CI, 0.27-0.46) with other biologics (log-rank P < .01).
When broken down by mechanism of action, drug changes occurred in 57.1% of patients receiving a TNFi (P < .001 vs risankizumab) and 25.5% of those on an IL-17 inhibitor (P = .268 vs risankizumab).¹ The corresponding probabilities of a drug change were noted as 0.59 (95% CI, 0.41-0.78) for TNFi and 0.25 (95% CI, 0.15-0.41) for IL-17 inhibitors (log-rank P < .001 across groups).
The study authors noted the results would support risankizumab therapy as a long-term option for individuals living with psoriasis and comorbid psoriatic arthritis.¹ Safety outcomes from VALUE have been reported separately.
Because this is a post hoc, observational analysis, it can’t show why patients changed therapy, and the matched sample was modest in size. The investigators were from Monash University, the University of Toronto, the University of Lübeck and AbbVie, which markets risankizumab.¹
Editor's Note: This summary has been edited for grammar and clarity using artificial intelligence tools.
References
Östör A, Papp KA, Lynde CW, et al. Drug survival of risankizumab vs other biologics in patients with psoriasis and comorbid psoriatic arthritis: final 3-year results from the VALUE study. Presented at: 2026 Fall Clinical Dermatology Conference; Las Vegas, NV. Dermatol Online J. doi:10.25251/v02x9723
Östör A, et al. Drug survival of risankizumab vs other biologics after 25 months of treatment among patients with psoriatic arthritis: an interim analysis of the VALUE study. Poster presented at: Fall Clinical Dermatology Conference; October 23-26, 2025; Las Vegas, NV.
